Tris Pharma Inc, a specialty pharmaceutical company, has signed a contract with Medison Pharma, an international commercial partner, it was reported on Tuesday.
The contract has been signed to give Medison Pharma exclusive rights to commercialise Tris Pharma's FDA-approved Quillivant treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Israel.
Meir Jakobsohn, Medison founder and CEO, was quoted as saying: "We view ADHD as an area in which there is a significant unmet need in Israel, and we believe that Quillivant XR is uniquely well-positioned for the paediatric market. As the only FDA-approved long-acting methylphenidate suspension, Quillivant XR is a natural fit for children who have difficulty swallowing pills, and who can benefit from both the once-per-day dosing schedule and the customised dose and titration enabled by a liquid product."
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial